Last reviewed · How we verify

NCT00951431

Gastric Functions & Proton Pump Inhibitor( PPI) Study

Completed Phase 4 Last updated 1 February 2019
What this trial tests

Phase 4 trial testing Esomeprazole in Functional Dyspepsia in 155 participants. Completed in 19 February 2016.

Timeline
3 December 2009
Primary endpoint
31 December 2015
19 February 2016

Quick facts

Lead sponsorChinese University of Hong Kong
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment155
Start date3 December 2009
Primary completion31 December 2015
Estimated completion19 February 2016
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 60, any sex, with Functional Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Functional dyspepsia is one of the most common digestive disorders. The pathophysiology of functional dyspepsia is uncertain. Proton pump inhibitor (PPI) has been recommended as the first line treatment for functional dyspepsia. However, the mechanism of symptom relief is unclear. Most of the previous studies were performed on healthy volunteers who received only a very short course of PPI. The correlation between symptom and gastric emptying is lacking in these studies. Demographic data and anthropometric measurements will be obtained for baseline assessment. Patients are required to complete FGI Screening Questionnaire, Functional dyspepsia symptom questionnaire, gastroesophageal reflux disease (GERD) symptom questionnaire and irritable bowel syndrome (IBS) symptom questionnaire to have a thorough assessment of their GI symptoms. (1) Satiety test and ghrelin profile, and (2)gastric emptying test will be arranged as two individual visits. After baseline investigations, patients will be randomly assigned to either Nexium 20 mg daily or identical looking placebo for 8 weeks. The patients will report their individual dyspeptic symptoms on weekly basis using a self-administered symptom questionnaire. Satiety test and ghrelin profile, gastric emptying study will be repeated at the end of 8-week treatment. Hypothesis: Long-term PPI relieves dyspeptic symptom through acceleration of gastric emptying rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Esomeprazole

Trials testing the same drug.

Other recruiting trials for Functional Dyspepsia

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00951431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing